Anzeige
Mehr »
Login
Samstag, 18.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
195 Leser
Artikel bewerten:
(1)

Inspira Financial's Study Reveals Increased Contributions Among Workers With Both HSAs and LPFSAs

Finanznachrichten News

The report suggests that workers could do more to take full advantage of these accounts.

OAK BROOK, IL / ACCESSWIRE / September 10, 2024 / Inspira Financial, a leading provider of health, wealth, retirement, and benefits solutions, today released a first-of-its kind study that examines the behavior of individuals who own both a health savings account (HSA) and a limited purpose flexible spending account (LPFSA). The key finding shows that employees with both an HSA and an LPFSA contribute more to their HSAs compared to those who only have an HSA. But based on distribution activity, workers are not fully taking advantage of these accounts and their tax saving benefits.

Inspira partnered with Employee Benefit Research Institute (EBRI) to examine its databases of nearly 300,000 HSA and FSA account holders and to understand behaviors around the usage of HSAs and LPFSAs.

"There's a clear message here: HSAs and LPFSAs can help workers realize tax savings, stretch health care dollars further than they otherwise could, and be better prepared for health care in retirement - but only when they are used together strategically," said Michael Eldredge, HSA Product Manager at Inspira. "We see an opportunity for employers to better position their employees for short- and long-term health care spending and saving success by pairing an LPFSA with an HSA and putting an education plan in place so employees know how these benefits can work together."

The study shows account holders who have both LPFSAs and HSAs are more actively engaged with their workplace benefits compared to those without LPFSAs. Regardless of the reason for their higher engagement, these workers are well-positioned to maximize tax savings.

However, contributions do not tell the entire story. Approximately 30% of employees with access to both an LPFSA and an HSA do not withdraw any funds from their LPFSA. The lack of distributions is concerning, as it could mean that these accountholders aren't getting the full benefits of their company's LPFSA. The report further breaks down this trend while offering suggestions for employers to take action.

"One approach that organizations can take is to suggest that workers can avoid withdrawing money, for dental and vision expenses, from their HSAs by participating in their employer's LPFSA offering. Although employees with an HSA cannot also have a health care FSA, they can still open an LPFSA if it's available through their employer," Eldredge said.

Read the full report

###

About Inspira Financial

Inspira Financial provides health, wealth, retirement, and benefits solutions that strengthen and simplify the health and wealth journey. With more than 8 million clients holding over $62 billion in assets under custody, Inspira works with thousands of employers, plan sponsors, recordkeepers, TPAs, and other institutional partners - helping the people they care about plan, save, and invest for a brighter future. Inspira relentlessly pursues better outcomes for all with our automatic rollover services, health savings accounts, emergency savings funds, custody services, and more. Learn more at inspirafinancial.com.

Contact Information

Casey Burke
Public Relations Manager
casey.burke@inspirafinancial.com

SOURCE: Inspira Financial

.

View the original press release on newswire.com.

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.